KBC Group
RCUS icon

KBC Group’s Arcus Biosciences RCUS Stock Holding History

KBC Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50K Buy
+2,334
New +$50.4K ﹤0.01% 1654
2024
Q2 		– Sell
-1,952
Closed -$37K – 1904
2024
Q1 		$37K Hold
1,952
– – ﹤0.01% 1698
2023
Q4 		$37K Hold
1,952
– – ﹤0.01% 1712
2023
Q3 		$35K Sell
1,952
-2,076
-52% -$41.7K ﹤0.01% 1715
2023
Q2 		$82K Hold
4,028
– – ﹤0.01% 1243
2023
Q1 		$73K Hold
4,028
– – ﹤0.01% 1297
2022
Q4 		$83K Hold
4,028
– – ﹤0.01% 1269
2022
Q3 		$105K Hold
4,028
– – ﹤0.01% 1166
2022
Q2 		$102K Buy
+4,028
New +$98.6K ﹤0.01% 1214

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

KBC Group's RCUS Position: Q1 2026 in Review

KBC Group opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 2,334 shares worth $50K. The stake represents ﹤0.01% of the portfolio and ranks #1654 among its holdings. This is a return to the name: KBC Group previously reported a position in RCUS as recently as Q1 2024.

KBC Group first reported a position in RCUS in Q2 2022 and has held it in 9 quarters since. The position peaked at $105K in Q3 2022. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • KBC Group held 2,334 shares of Arcus Biosciences worth $50K as of Q1 2026.
  • Arcus Biosciences was a new KBC Group position in Q1 2026.
  • Arcus Biosciences made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1654 holding.
  • KBC Group first reported a position in Arcus Biosciences in Q2 2022 and has held it in 9 quarters since.
  • KBC Group's Arcus Biosciences position peaked at $105K in Q3 2022.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.